News: Phylogica’s peptide fusions kill aggressive cancer cells

Phylogica (ASX:PYC) has completed a pilot study that demonstrates that its cell penetrating peptides linked with the Omomyc drug kills aggressive, drug resistant breast cancer cells.

The study by Associate Professor Pilar Blancafort, one of Australia’s leading breast cancer experts, also observed the company’s CPP fusion improves the efficacy of existing anticancer drugs.

For example, a combination of Cetuximab and a Phylomer CPP-Omomyc fusion was more than three times more effective at killing drug resistant breast cancer cells than either of these agents alone.

Phylogica’s CPP fusion also resulted in a substantial reduction in tumour size in an in vivo breast cancer model.

The pilot study will need to be repeated using larger groups to confirm its significance.

The ability of Phylogica’s delivery system to kill cancers from the inside and improve the efficacy of existing drugs opens up the intracellular target landscape to next generation biologics drugs such as proteins.

Its platform is based on its proprietary Phylomer libraries containing over 400 billion unique natural peptides, which have been optimised by evolutionary selection to adopt stable drug-like structures.

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.